Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study

References

• Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 2011;377:529-32
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl V):v1-v52
   PubMedGoogle Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):S1-113
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Lipid modification. London, UK: National Institute for Health and Clinical Excellence, 2008 Jun 17. Report No.: CG67
   Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68
   PubMed Web of Science ®Google Scholar
• Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95:2015-22
   PubMed Web of Science ®Google Scholar
• Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10:373-87
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
   PubMed Web of Science ®Google Scholar
• Franc S, Dejager S, Bruckert E, et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003;17:459-65
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO Study. Cardiovasc Drugs Ther 2005;19:403-14
   PubMed Web of Science ®Google Scholar
• Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89C-94C
   PubMed Web of Science ®Google Scholar
• Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97:61C-8C
   Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008;337:a1095
   PubMed Web of Science ®Google Scholar
• Siddiqi SA, Thompson PD. How do you treat patients with myalgia who take statins? Curr Atheroscler Rep 2009;11:9-14
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:69C-76C
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, et al. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010;8:632-7
   PubMed Web of Science ®Google Scholar
• Molokhia M, McKeigue P, Curcin V, et al. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS ONE 2008;3:e2522
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Dunselman P, Wedel H, et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol 2010;56:1196-204
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7
   PubMed Web of Science ®Google Scholar
• Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011;215:23-9
   PubMed Web of Science ®Google Scholar
• Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis–myalgia in statin-treated patients. Transl Res 2009;153:11-16
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Budhani SB, Masineni SS, et al. Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance. Curr Med Res Opin 2011;27:1683-90
   PubMed Web of Science ®Google Scholar
• Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2010 Mar 27. [Epub ahead of print]
   Web of Science ®Google Scholar
• Rejnmark L, Vestergaard P, Heickendorff L, et al. Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010;2010:957174
   PubMedGoogle Scholar
• Alonso-Org S, Moreno L, Macaya C, et al. Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 2006;5:2301-8
   PubMed Web of Science ®Google Scholar
• Posvar EL, Radulovic LL, Cilla DD Jr, et al. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36:728-31
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116-21
   PubMed Web of Science ®Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28
   PubMed Web of Science ®Google Scholar
• Backes JM, Moriarty PM, Ruisinger JF, et al. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007;100:554-5
   PubMed Web of Science ®Google Scholar
• Ruisinger JF, Backes JM, Gibson CA, et al. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009;103:393-4
   PubMed Web of Science ®Google Scholar
• Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6
   PubMed Web of Science ®Google Scholar
• Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101:1747-8
   PubMed Web of Science ®Google Scholar
• Mackie BD, Satija S, Nell C, et al. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol 2007;99:291
   PubMed Web of Science ®Google Scholar
• Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol 2011;5:308-15
   PubMed Web of Science ®Google Scholar